Myths and Facts About Oral GLP-1s for Obesity
Health ConditionsObesity

8 Misconceptions and Facts About Oral GLP-1s for Obesity

8 Misconceptions and Facts About Oral GLP-1s for Obesity
Adobe Stock
By
Published on September 28, 2026
by
Add us on Google

The idea of taking a glucagon-like peptide-1 (GLP-1) medication in pill form rather than an injection may sound appealing, especially if you’re uneasy around needles. But oral GLP-1s can come with trade-offs of their own.

For starters, the oral version of Wegovy (semaglutide) or Foundayo (orforglipron) isn’t necessarily more convenient than an injection, says Brynna Connor, MD, a board-certified family medicine physician in private practice in Austin, Texas, and a healthcare ambassador at NorthWestPharmacy.com. Nor is it guaranteed to give you better results.

Rather, the best option for you will depend on your health history, weight loss goals, other medications you may be taking, and your ability to follow the dosing instructions, she says.

Here are eight other myths and facts to know about oral GLP-1s for obesity.

1. Myth: Oral GLP-1s Are Just as Effective as Injectable GLP-1s

While effective, oral GLP-1s tend to produce less average weight loss than the injectable versions, says Meghan Garcia-Webb, MD, a triple board-certified internal medicine, lifestyle medicine, and obesity medicine physician in private practice and an internist at Beth Israel Lahey Health Primary Care in Wellesley, Massachusetts.

One study found that people taking 25 milligrams (mg) of oral semaglutide daily lost an average of nearly 14 percent of their starting weight, whereas other research has found that people taking 7.2 mg of the injectable semaglutide lost nearly 19 percent of their body weight.

In a clinical trial of Foundayo, which doesn’t have an injectable version, people taking an earlier formulation equivalent to the maximum dose approved by the U.S. Food and Drug Administration (FDA) lost an average of about 11 percent of their starting weight.

 For someone starting at 200 pounds (lb), that would equal about 22 lb of weight loss.
Other injectable GLP-1s for obesity, such as a 15 mg dose of Zepbound (tirzepatide), have resulted in an average weight loss of 21 percent of a person’s starting weight — about 42 lb for someone with a baseline weight of 200 lb.


It’s important to note that these weight loss percentages come from different clinical trials and are not direct comparisons. Plus, adds Dr. Connor, oral GLP-1 medications approved for obesity are relatively new, so more research is needed.

2. Fact: Oral and Injectable GLP-1s Don’t Contain the Same Dosage — for a Reason

Both Wegovy tablets and injections contain semaglutide, but the tablet isn’t simply the injectable medication distilled into pill form, says Connor.

When you take a Wegovy tablet, for instance, your body’s digestive enzymes break down some of the active ingredient before it reaches the bloodstream.

 That’s one reason the tablets contain more of the active ingredient than the injections — and why that doesn’t necessarily mean your body is receiving a higher dose, she says.
As for Foundayo, it’s easy to assume it’s a pill version of Zepbound, especially since the same pharmaceutical company makes both these medications, says Dr. Garcia-Webb. But they’re not interchangeable. Foundayo contains orforglipron and specifically targets GLP-1 receptors (which help regulate appetite).

 Zepbound, though, contains tirzepatide and targets both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors, which also play a role in regulating appetite.

If you switch GLP-1 medications or formulations, follow the instructions for the new prescription. The dose, timing, and steps for increasing the dose may be different.

3. Myth: Oral GLP-1 Pills Are Easier to Stick to Over the Long-Term


It’s not uncommon for people to stop taking a GLP-1 because of the side effects, regardless of whether it comes in a pill or injection.

In one follow-up study of injectable semaglutide, for instance, people regained about two-thirds of the weight they had lost within one year of stopping the medication.

 This research didn’t examine the pill form, but both the oral and injectable forms of semaglutide contain the same active ingredient and work through the same pathway, Garcia-Webb says.

The bottom line: Taking a pill doesn’t necessarily mean you’ll be able to use it for the long-term. How long you take an oral GLP-1 depends on its benefits, side effects, cost, and your health needs.

4. Fact: Oral GLP-1s Can Cause Many of the Same Side Effects as the Injectables

Taking a GLP-1 by mouth doesn’t necessarily mean it’s easier to tolerate. “The side effects aren’t caused by the delivery method, but instead by the medication itself,” Connor says.

Common side effects of oral GLP-1s are similar to those of injectable GLP-1s, and include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach discomfort
  • Fatigue
Both oral and injectable GLP-1s also carry some similar, less common but potentially serious risks. These include pancreatitis (inflammation of the pancreas), gallbladder problems, severe digestive problems, and kidney injury caused by dehydration.

With oral GLP-1s, side effects are often most noticeable when you first start treatment or increase the dose, and may ease over time, Connor says. Contact your healthcare provider if you develop severe or persistent symptoms.

5. Myth: Oral GLP-1s Make Your Body Burn Calories Faster

There are plenty of pills and supplements that claim to be “metabolism boosters.” An oral GLP-1, however, isn’t one of them.

GLP-1 medications don’t speed up your metabolism or make your body burn calories faster, Connor says. Instead, they help reduce hunger and help you reach a sense of fullness sooner.

They can also slow the rate at which food leaves your stomach, which may help you stay full longer after eating.

“It’s not uncommon for people [taking GLP-1 medications] to report that they’re not thinking about food as much,” Connor says. You may also feel satisfied with smaller portions or have less desire to keep eating after a meal. Together, these effects may make a reduced-calorie eating plan easier to follow when taking a GLP-1 medication.

6. Fact: A GLP-1 Pill Isn’t Necessarily More Convenient Than an Injection

Popping a pill may sound simpler than giving yourself an injection, but oral GLP-1s require some prep work, too.

If you’re prescribed semaglutide tablets, for example, you’ll need to take the medication in the morning on an empty stomach with no more than 4 ounces of plain water. You must then wait at least 30 minutes before eating, drinking, or taking other medications by mouth.

 Skipping these steps may reduce how much semaglutide your body absorbs, which can make the medication less effective, Connor says.
By comparison, you take injectable semagultide once a week, at any time of day, with or without food.

 For some people, that schedule may be more manageable than following the tablet instructions.
Orforglipron, however, has fewer timing restrictions — you take it once daily, at any time and with or without food.

7. Myth: You Can Eat Whatever You Want (and Skip Exercise) While Taking an Oral GLP-1

While you may eat smaller portions or have fewer cravings for certain foods, your body still needs nutrients and adequate fluids when you take a GLP-1, Connor says.

Semaglutide tablets and orforglipron are intended for use with a reduced-calorie eating plan and increased physical activity.

 Connor recommends viewing these medications as tools that can make healthy habits more achievable, not as a replacement for them.
Moreover, people taking both oral and injectable GLP-1s can lose muscle as well as fat — and losing too much muscle can interfere with your strength, balance, and stamina, making daily activities difficult and increasing the risk of falls, especially with age.

To preserve muscle mass, you’ll need to do strength-training exercises and eat enough protein.

 Some experts recommend getting more than 1.2 grams (g) of protein per kilogram (kg) of body weight (or about .55 g per lb) daily while using a GLP-1 medication,

 but your needs may differ, so talk to your care team or a registered dietitian first.

8. Fact: Oral and Injectable GLP-1 Medications Should Not Be Combined

“[Oral and injectable GLP-1 medications] should absolutely not be combined,” Garcia-Webb says. “Combining them is not safe or indicated for obesity treatment,” she adds.

That includes taking semaglutide tablets and orforglipron together or taking these medications with any other injectable GLP-1.

Healthcare providers may sometimes prescribe a GLP-1 along with an older non-GLP-1 weight loss medication, such as phentermine, which works differently, Garcia-Webb says. Not only does this type of combination require strict guidance from a prescriber, it’s different from taking two GLP-1 medications, which is not recommended, she notes.

If you’re changing from an injectable GLP-1 to an oral version or vice versa, follow your prescriber’s recommendation for when to stop the first medication and begin the new one.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine. September 17, 2025.
  2. Wharton S et al. Once-Weekly Semaglutide 7·2 mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial. The Lancet Diabetes & Endocrinology. November 2025.
  3. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. September 16, 2025.
  4. ZEPBOUND- tirzepatide Injection, Solution. DailyMed. August 28, 2026.
  5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. June 4, 2022.
  6. WEGOVY- Semaglutide Injection, Solution WEGOVY- Semaglutide Tablet. DailyMed. June 18, 2026.
  7. FOUNDAYO- Orforglipron Tablet, Film Coated. DailyMed. July 29, 2026.
  8. DiStefano MJ et al. Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Among US Adults: A National Survey. Journal of Managed Care & Specialty Pharmacy. July 27, 2026.
  9. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The Step 1 Trial Extension. Diabetes. April 19, 2022.
  10. Rossi G et al. Muscle Loss and GLP-1R Agonists Use. Acta Diabetologica. November 7, 2025.
  11. Sarcopenia. Cleveland Clinic. April 2, 2026.
  12. Noronha JC et al. Optimizing GLP-1 Therapies for Obesity and Diabetes Management. Obesity Pillars. December 2025.
  13. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. April 1, 2026.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Natalia-Johnsen-bio

Natalia Johnsen, MD

Medical Reviewer
Member of American College of Lifestyle Medicine

Natalia Johnsen, MD, is a triple board-certified physician in internal medicine, lifestyle medicine, and obesity medicine, practicing as an internist and consultant at the Vancouve...

See full bio
Maggie-Aime-bio

Maggie Aime, MSN, RN

Author

Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content. Her extensive nursing ba...

See full bio
See Our Editorial PolicyMeet Our Health Expert Network